This conception is supported by previously published experimental data showing that overexpression of PPARα leads to lipid accumulation and the development of DCM (84), and that pharmacological inhibition of PPARα reduces cardiac lipotoxicity in diabetes (84, 85). The gene discussed is PPARA; the disease is familial dilated cardiomyopathy.